Cancerlysins™: A Revolution in Targeted Cancer Therapy
IMV-M™ is engineered with a unique combination of features including precisely calibrated binding affinities that enhance both safety and activity.
DISCOVERY
IN-VITRO
VALIDATION
VALIDATION
IN-VIVO
VALIDATION
VALIDATION
CMC-READY
IMV-M™NSCLC, Gynecologic & Pancreatic
DISCOVERY
IN-VITRO
IN-VIVO
CMC-READY
IMV-CColorectal, Gastric & Breast
DISCOVERY
IN-VITRO
IMV-1Prostate & Melanoma
DISCOVERY
IMV-2Urothelial & Gastrointestinal
DISCOVERY
IMV-3Ovarian & Endometrial
DISCOVERY
IMV-4Multiple Myeloma, Non-Hodgkin Lymphoma & Chronic Lymphocytic Leukemia
DISCOVERY
IMV-5Acute Myeloid Leukemia
DISCOVERY
IMV-M™ Details
IMV-M™ clustering on MUC16
Multiple IMV-M™ molecules bind to the same MUC16 molecule*, enforcing DR5 crowding on the opposite end, ensuring MUC16-selective DR5 clustering.
Optimized Geometry
Flexible linkers between the IMV-M™ components allow optimal DR5 clustering geometry.
Binding Selectivity
High anti-MUC16 affinity and low anti-DR5 affinity ensure DR5 binding occurs only after IMV-M™ binds to MUC16, providing MUC16-selective DR5 activation.
Broad IP Protection
Written opinion of International Patent Examiner confirmed Novelty, Inventive Step, and Industrial Applicability of IMV-M™ patent claims.
*DOI: 10.1158/0008-5472.CAN-06-4512